Osteoporosis International

, Volume 17, Issue 8, pp 1141–1145 | Cite as

Calcium supplementation does not affect CRP levels in postmenopausal women – a randomized controlled trial

  • A. GreyEmail author
  • G. Gamble
  • R. Ames
  • A. Horne
  • B. Mason
  • I. R. Reid
Original Article



Epidemiological studies suggest that calcium supplementation may decrease the risk of cardiovascular disease.


Since the inflammatory marker C-reactive protein (CRP) is a risk factor for cardiovascular disease, and CRP production is potentially responsive to parathyroid hormone, we measured high-sensitivity CRP at baseline and 12 months in a subset of healthy postmenopausal women participating in a randomized controlled trial of the effects of 1 g of calcium daily on the incidence of fractures.


At baseline, we found that CRP correlated positively with indices of body weight and fat and with bone mineral density (BMD) at the total body and total hip sites, but the associations between CRP and BMD were lost after adjustment for body weight. There were consistent associations between levels of CRP and markers of the metabolic syndrome (fat mass, plasma triglycerides, fasting glucose).


After 1 year of calcium supplementation, there was no difference between the groups in levels of CRP. We conclude that levels of CRP correlate with anthropometric and biochemical features of insulin resistance, but that they are neither predictive of BMD nor affected by 1 g of calcium supplementation in healthy postmenopausal women.


Bone density Calcium C-reactive protein Inflammation 



This research has been funded by the Health Research Council of New Zealand.


  1. 1.
    Reid IR (1996) Therapy of osteoporosis: calcium, vitamin D, and exercise. Am J Med Sci 312:278–286CrossRefPubMedGoogle Scholar
  2. 2.
    Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1993) Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 328:460–464CrossRefPubMedGoogle Scholar
  3. 3.
    Prince RL, Devine A, Dhaliwal SS, Dick IM (2004) Results of a 5 year double blind, placebo controlled trial of calcium supplementation (CAIFOS); clinical fracture outcomes (abstract). J Bone Miner Res 19:S3CrossRefGoogle Scholar
  4. 4.
    Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98:331–335CrossRefPubMedGoogle Scholar
  5. 5.
    Bostick RM, Kushi LH, Wu Y, Meyer KA, Sellers TA, Folsom AR (1999) Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol 149:151–161PubMedGoogle Scholar
  6. 6.
    Knox EG (1973) Ischaemic-heart-disease mortality and dietary intake of calcium. Lancet 1:1465–1467CrossRefPubMedGoogle Scholar
  7. 7.
    Dawson EB, Frey MJ, Moore TD, McGanity WJ (1978) Relationship of metal metabolism to vascular disease mortality rates in Texas. Am J Clin Nutr 31:1188–1197PubMedGoogle Scholar
  8. 8.
    Reid IR, Mason B, Horne A et al (2002) Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. Am J Med 112:343–347CrossRefPubMedGoogle Scholar
  9. 9.
    Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454CrossRefPubMedGoogle Scholar
  10. 10.
    Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397CrossRefPubMedGoogle Scholar
  11. 11.
    Retterstol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K (2002) C-reactive protein predicts death in patients with previous premature myocardial infarction-a 10 year follow-up study. Atherosclerosis 160:433–440CrossRefPubMedGoogle Scholar
  12. 12.
    Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMedGoogle Scholar
  13. 13.
    Labarrere CA, Zaloga GP (2004) C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 117:499–507CrossRefPubMedGoogle Scholar
  14. 14.
    Grey A, Mitnick MA, Masiukiewicz U et al (1999) A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 140:4683–4690CrossRefPubMedGoogle Scholar
  15. 15.
    Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K (1996) Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption-a clinical research center study. J Clin Endocrinol Metab 81:3450–3454CrossRefPubMedGoogle Scholar
  16. 16.
    Mitnick MA, Grey A, Masiukiewicz U et al (2001) Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab 280:E405–E412PubMedGoogle Scholar
  17. 17.
    Gannage-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R (2003) Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest 26:748–753PubMedGoogle Scholar
  18. 18.
    Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305–311CrossRefPubMedGoogle Scholar
  19. 19.
    Raisz LG (1988) Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 318:818–828PubMedCrossRefGoogle Scholar
  20. 20.
    Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2003) Predictors of bone mineral density and osteoporosis in patients attending a rheumatology outpatient clinic. Rheumatol Int 23:67–69CrossRefPubMedGoogle Scholar
  21. 21.
    Speden DJ, Calin AI, Ring FJ, Bhalla AK (2002) Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 29:516–521PubMedGoogle Scholar
  22. 22.
    Forouhi NG, Sattar N, McKeigue PM (2001) Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 25:1327–1331CrossRefPubMedGoogle Scholar
  23. 23.
    Guerrero-Romero F, Rodriguez-Moran M (2003) Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab 29:65–71PubMedCrossRefGoogle Scholar
  24. 24.
    Hak AE, Stehouwer CD, Bots ML et al (1999) Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986–1991PubMedGoogle Scholar
  25. 25.
    Lemieux I, Pascot A, Prud’homme D et al (2001) Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 21:961–967PubMedGoogle Scholar
  26. 26.
    Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G (2001) C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 25:1416–1420CrossRefPubMedGoogle Scholar
  27. 27.
    Rifai N (2001) C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol 1:153–157CrossRefPubMedGoogle Scholar
  28. 28.
    Wu DM, Chu NF, Shen MH, Chang JB (2003) Plasma C-reactive protein levels and their relationship to anthropometric and lipid characteristics among children. J Clin Epidemiol 56:94–100CrossRefPubMedGoogle Scholar
  29. 29.
    Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET (2002) Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105:564–569CrossRefPubMedGoogle Scholar
  30. 30.
    Kerner A, Avizohar O, Sella R et al (2005) Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 25:193–197PubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2006

Authors and Affiliations

  • A. Grey
    • 1
    Email author
  • G. Gamble
    • 1
  • R. Ames
    • 1
  • A. Horne
    • 1
  • B. Mason
    • 1
  • I. R. Reid
    • 1
  1. 1.Department of MedicineUniversity of AucklandAucklandNew Zealand

Personalised recommendations